Alfuzozin Aurobindo

Quick links

Choose a section

Quick links to important sections

Advertisements

Alfuzozin Aurobindo

Advertisements
Advertisements
Advertisements

Overview of Alfuzozin Aurobindo

What is Alfuzozin Aurobindo?

Alfuzozin Aurobindo is a medication containing the active substance alfuzosin hydrochloride. It belongs to a group of medicines known as alpha-1-adrenoreceptor antagonists, or alpha-blockers.

Mechanism of Action

This medication works by relaxing the smooth muscles in the prostate gland and the neck of the bladder. The prostate gland surrounds the urethra, which is the tube through which urine passes out of the body. When the prostate gland becomes enlarged, it can press against the urethra, making it difficult to urinate comfortably.

By facilitating the relaxation of these specific muscle fibers, alfuzosin helps to reduce the mechanical obstruction to urine flow. This action allows urine to flow more easily and helps alleviate the urinary symptoms associated with an enlarged prostate.

Therapeutic Use

Alfuzozin Aurobindo is used to manage the functional symptoms of Benign Prostatic Hyperplasia (BPH). BPH is a non-cancerous condition where the prostate gland increases in size, commonly occurring in aging men. The symptoms addressed by this treatment typically include:

  • A weak or interrupted urinary stream
  • Straining to urinate
  • A feeling of incomplete bladder emptying
  • Frequent urges to urinate, especially during the night
  • Urgency or difficulty in starting urination

Regulatory References

  1. ALFUZOSIN HYDROCHLORIDE Extended-Release Tablet Labeling
  2. Alpha 1 Adrenergic Receptor Antagonists (NIH/LiverTox)
Advertisements

What side effects are possible with Alfuzozin Aurobindo?

Possible side effects and safety information

Alfuzosin's official safety profile, documented in regulatory texts like the EMA SmPC and FDA Prescribing Information, classifies adverse reactions by frequency and the body system affected. These classifications quantify the expectedness of effects based on clinical and post-marketing data.

Frequency-Classified Adverse Reactions

Side effects related to the medicine's vascular activity are common, particularly effects on the Nervous and Vascular Systems.

Classification Examples of Documented Effects
Common (1 to 10 in 100) Dizziness, Headache, Postural Hypotension (a drop in blood pressure upon standing), Asthenia (tiredness), Nausea.
Uncommon (1 to 10 in 1,000) Syncope (fainting), Tachycardia (fast heartbeat), Palpitations, Diarrhea, Rash, Edema.
Very Rare/Not Known Angioedema, Priapism, Hepatocellular injury, Intraoperative Floppy Iris Syndrome (IFIS).

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions officially documented, although rare, include Syncope, Priapism (a prolonged erection), Angioedema, and reports of Hepatocellular Injury.

The label defines specific safety constraints. Use is contraindicated in patients with a history of Orthostatic Hypotension and in individuals with severe hepatic impairment. There is an explicit safety note regarding the risk of Intraoperative Floppy Iris Syndrome (IFIS), a complication observed during cataract surgery, which is classified under the Eye Disorders System-Organ Class. These constraints structure the official risk profile by identifying populations and circumstances where use is restricted or requires caution.

Time- and Population-Specific Patterns

The risk of effects such as Postural Hypotension and Dizziness is officially noted to occur primarily at the beginning of treatment. Regulatory documents also highlight that the risk of hypotension may be greater in older adults.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is strictly derived from official government regulatory documents detailing the documented manifestations of Alfuzosin overdose and the required emergency actions.


Documented Clinical Manifestations and Required Actions

Overdose of Alfuzosin is primarily characterized by hypotension (low blood pressure), which is the main manifestation documented in prescribing information. A significant or pronounced drop in blood pressure may occur, which can be accompanied by symptoms such as dizziness or fainting (syncope).

Regulatory guidance requires that patients experiencing a suspected overdose be hospitalized and kept in the supine position (lying on their back). Management is strictly symptomatic and supportive, focusing on the conventional treatment of hypotension, which may include administering a vasopressor or measures for vascular volume expansion.


When Immediate Medical Help is Required

Official labeling mandates that immediate medical assistance must be sought for any suspected overdose or for symptoms of low blood pressure. Emergency services should be contacted immediately or the patient should go to the nearest hospital emergency department if too much of the drug has been taken. Furthermore, immediate medical care is required if the specific severe complication of priapism (a painful, prolonged erection) lasts longer than four hours, as documented in post-marketing reports.


Management Considerations

Regulatory documents state that no specific antidote is known for Alfuzosin overdose. Due to the high degree of protein binding, the substance is not dialyzable.

Advertisements

Therapeutic Uses of Alfuzozin Aurobindo

What Alfuzosin Aurobindo Treats: Main Uses and Benefits

Alfuzosin is primarily used for managing the functional symptoms of benign prostatic hyperplasia (BPH) in men. BPH is one of the conditions presenting with systemic or localized discomfort, often related to lower urinary tract symptoms (LUTS).

Alfuzosin is commonly used to help with the symptoms associated with BPH. This supports the management of symptoms related to inflammatory or irritative states and symptoms of increased neurological or muscular activity. This includes symptoms related to physical discomfort and symptoms that interfere with daily functioning. The medication is commonly used across conditions presenting with acute episodes and provides supportive relief when symptoms intensify and symptomatic assistance is needed.

“This medication helps maintain a sense of stability when symptoms are more noticeable and assists with maintaining functional stability during symptomatic phases.”

It is relevant in contexts involving heightened systemic burden or temporary physiological imbalance. Alfuzosin is generally used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed, and is relevant in contexts marked by increased discomfort or tension.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning


Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Alfuzosin Aurobindo is officially labeled for use in adult males to manage the functional symptoms of benign prostatic hyperplasia (BPH). Its use is defined by a series of mandatory regulatory exclusions related to pre-existing health conditions and concurrent medications.

Population Status Regulatory Classification (Official Labeling)
Eligible Population Adult males; Older adults (Geriatric use is established; dose adjustment not typically needed)
Not Indicated Pediatric population (Safety/efficacy not established); Women (Drug is not indicated)

Contraindications (Must Not Use)

The medicine is strictly contraindicated and must not be used by patients with the following conditions or circumstances, as stated in official regulatory documents:

  • Moderate or Severe Hepatic Impairment: Prohibited due to a significant increase in drug exposure in patients with Child-Pugh categories B and C liver disease.
  • Hypersensitivity: Patients with known allergies to alfuzosin hydrochloride, other quinazoline derivatives, or any component of the tablet.
  • Orthostatic Hypotension History: Individuals with a history of symptomatic low blood pressure upon standing.
  • Concomitant Alpha-1-Blockers: Prohibited for patients currently taking any other alpha-1 adrenergic antagonist.
  • Potent CYP3A4 Inhibitors: Prohibited when taken with potent CYP3A4 enzyme inhibitors (e.g., ketoconazole, ritonavir) due to increased blood levels of alfuzosin.

Restricted or Conditional Use

Caution should be exercised when administering to patients with severe renal impairment (creatinine clearance <30 mL/min) due to limited clinical safety data. Caution is also necessary for patients with mild hepatic impairment or those with a history of QT prolongation.

Advertisements

What should I know about interactions with other medicines?

Alfuzosin is metabolized principally by the liver enzyme CYP3A4, which is the basis for its most critical interactions, along with its alpha-blocking effects that cause vasodilation.

Contraindicated Combinations

Alfuzosin must not be taken with the following categories of medicinal products:

  • Potent CYP3A4 Inhibitors: Co-administration with potent inhibitors (such as ketoconazole, itraconazole, or ritonavir) is strictly avoided. This combination significantly increases alfuzosin concentration in the bloodstream, raising the risk of severe side effects, including symptomatic hypotension.
  • Other Alpha-1 Adrenergic Antagonists: Concomitant use with other alpha-blockers is not permitted, as the pharmacodynamic interactions can lead to excessive blood pressure lowering effects.

Combinations Requiring Caution

Increased monitoring and caution are required when Alfuzosin is taken with the following medicines or product classes due to the risk of additive hypotensive effects:

  • Antihypertensive Medication: Co-administration with drugs used to treat high blood pressure, such as beta-blockers (e.g., atenolol) and calcium channel blockers (e.g., diltiazem), may increase the risk of low blood pressure, postural hypotension, and fainting (syncope).
  • Nitrates: Use with nitrates can increase the potential for hypotension.
  • Phosphodiesterase-5 (PDE5) Inhibitors: These vasodilating agents (used for erectile dysfunction) may cause symptomatic hypotension when combined with alfuzosin.

Alfuzosin does not appear to interact significantly with drugs like warfarin or digoxin. Caution is also advised for use in patients with a history of QT prolongation or those taking medications known to prolong the QT interval.

Advertisements

Mechanism of Action

Selective Alpha-1 Receptor Blockade

Alfuzosin acts within the mechanistic domain involving receptor-mediated signaling by functioning as a selective competitive antagonist of post-synaptic alpha-1 (alpha1) adrenergic receptors. This targeted action interrupts the signal transmission mediated by sympathetic neurotransmitters (such as norepinephrine) that drive smooth muscle contraction.


Modulation of Lower Urinary Tract Smooth Muscle Tone

This mechanism engages pathways that regulate peripheral smooth muscle activity, primarily within the smooth muscle tissue of the prostate, prostatic capsule, and bladder neck, where alpha1-receptors are concentrated. The alpha1-receptor blockade initiates a sequence that mediates relaxation of the smooth muscle tissue in these areas, leading to a reduction in local tissue tension and outflow resistance.


Urodynamic Parameter Modulation

The final mechanistic cascade modifies early molecular steps that shape systemic physiological outcomes. The resulting physiological consequence is expressed as a modulation of urodynamic parameters, specifically an increase in the measured urinary flow velocity and a reduction of the remaining post-void volume.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Alfuzosin Aurobindo is administered as a 10 mg extended-release tablet and is intended strictly for oral use, following a specific administration protocol detailed in the product labeling. The official regimen is designed to sustain the release of the active substance over a prolonged period.


Dosing and Physical Handling

The standard prescribed dose is 10 mg taken once daily (qDay). To ensure proper absorption and the intended therapeutic effect, the tablet must be taken immediately after the same meal each day. It is critical that the extended-release tablet must be swallowed whole and must not be crushed, chewed, or divided; failure to do so can lead to an undesirable rapid release of the alfuzosin.


Specific Use Instructions

Category Official Instruction
Route & Form Oral administration of the 10 mg extended-release tablet
Frequency & Timing Once daily with a mandatory intake immediately after the same meal each day
Missed Dose If a dose is missed, skip the missed dose and take the next tablet at the regularly scheduled time; do not take a double dose
Older Adults Dose adjustment is generally not necessary for adults over 65 years
Pediatric Use Use of this medicine is not indicated for the pediatric population
Renal/Hepatic Status Caution should be exercised in patients with severe renal impairment; use is contraindicated in moderate or severe hepatic impairment

These official instructions establish the foundational structure for using the medication, defining the fixed dosage, specific timing relative to food intake, and the mandatory handling procedure necessary for the specialized extended-release formulation to function as intended.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alfuzozin Aurobindo

Evidence Base for Symptoms of Benign Prostatic Hyperplasia (BPH)

The core research for this medicine focused on its use in conditions marked by functional limitations, specifically lower urinary tract symptoms (LUTS) associated with BPH. The available evidence is largely derived from randomized controlled trials (RCTs), where adult men with moderate to severe symptoms were compared to a group receiving a placebo. These studies primarily monitored changes in standardized measurements of symptom severity (IPSS) and functional measures like the Peak Urinary Flow Rate ( Q max).

Studies report how symptoms evolved in the observed populations in the short-term, with findings indicating that symptomatic and objective functional measurements described patterns of change that were measured in the active treatment group compared to the placebo group. Research highlights changes measured during the study period in patient-reported outcomes describing perceived discomfort and activity level.

Studies for Acute Urinary Retention (AUR) Management)

The medicine was studied for use in a specific, acute clinical scenario: managing men who have experienced a first spontaneous episode of acute urinary retention (AUR) due to BPH. These randomized, placebo-controlled trials were applied in studies examining short-term symptom patterns around the Trial Without Catheter (TWOC) procedure. Data show patterns related to the rate of successful voiding in the immediate acute phase when compared to placebo.

Research on Ureteral Stone Passage (Medical Expulsive Therapy)

The evidence for the use of this medicine in conditions characterized by physical discomfort due to ureteral stones is compiled from systematic reviews and meta-analyses. This research examined outcomes related to stone expulsion rates and the time required for stone passage. Studies reported measurements of patterns of reduced expulsion times and data show patterns related to the stone-free status when measured against a control group not receiving an alpha-blocker.

Uncertainties and Gaps in the Research Record

A complete review of the evidence highlights several areas where the data are still emerging or remain constrained. For BPH, the research does not determine a long-term benefit for preventing key progression events like the primary occurrence of AUR. Furthermore, evidence quality varies across studies for the stone indication, and follow-up durations were limited in many primary trials, meaning that long-term outcomes are not fully characterized in the current research landscape.

Key Studies & References

  1. Public Assessment Report Scientific discussion Alfuzosine HCl Aurobindo 10 mg, prolonged-release tablets
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Alfuzozin Aurobindo (FAQ)

Q: How quickly should I expect to see an improvement in my urinary symptoms after starting Alfuzozin Aurobindo?

Clinical studies have shown that symptomatic improvement can be observed relatively early in the treatment course. Official product information suggests the largest observed changes in symptoms and urine flow generally occur between six weeks and three months.

Q: What's the typical time frame for Alfuzozin Aurobindo to fully start working?

Based on clinical trial data, the greatest symptomatic changes in urinary flow rate and overall severity were measured around six weeks to three months. This timeframe is when the medication is expected to provide its sustained symptomatic benefit for managing BPH.

Q: Does Alfuzozin Aurobindo cause problems with blood pressure, even if I don't have high blood pressure?

Yes, regulatory documents note that this medicine can cause a drop in blood pressure, known as postural hypotension, which happens when standing up quickly. This effect is a known side effect that can occur in any patient, regardless of whether they have pre-existing high blood pressure.

Q: Are dizzy spells a common side effect when first taking Alfuzozin Aurobindo?

Dizziness is a common side effect listed in the official product information. Furthermore, the risk for both dizziness and low blood pressure upon standing is officially noted to be highest primarily at the beginning of treatment.

Q: Is it normal to feel tired or fatigued while on Alfuzozin Aurobindo?

Yes, tiredness or fatigue is a known, common side effect. The official safety information lists asthenia (a medical term for tiredness or lack of energy) among the documented adverse reactions.

Q: Can Alfuzozin Aurobindo affect a person's sexual health?

Official safety documents list potential effects on sexual health. A prolonged, painful erection called Priapism is classified as a very rare, serious adverse reaction. Additionally, disorders related to ejaculation are classified as an uncommon effect.

Q: What should I do if I think Alfuzozin Aurobindo is not working for me?

Regulatory guidance emphasizes that if your symptoms do not improve or if you feel your condition is worsening, you should reach out to a healthcare provider. This allows a healthcare provider to assess your response to the medication.

Q: Does Alfuzozin Aurobindo relax muscles in the prostate or the bladder?

The medicine works to relax the smooth muscle tissue found in the prostate, the prostatic capsule, and the bladder neck. This relaxation helps reduce resistance and facilitates urine flow.

Q: Is it normal to wake up less often at night to urinate when taking Alfuzozin Aurobindo?

Since the medicine is used to treat lower urinary tract symptoms associated with BPH, and these often include nocturia (waking up at night to urinate), an improvement in this specific symptom is an expected therapeutic benefit described in clinical studies.

Q: What studies or research support the use of Alfuzozin Aurobindo for urinary issues?

The efficacy of this medication is based on evidence from randomized, placebo-controlled clinical trials. These studies demonstrated that the active treatment group had a greater improvement in BPH symptom scores and maximum urinary flow rate compared to the placebo group.

Q: Can I drive a car while taking Alfuzozin Aurobindo?

The official label advises caution regarding driving or operating hazardous machinery, especially during the start of treatment. This is due to the potential for side effects like dizziness, weakness, or fainting (syncope).

Q: What is the shelf life of Alfuzozin Aurobindo, and how should it be stored?

The tablets must be stored at a controlled room temperature, generally between 20 C and 25 C. You must keep the medicine protected from heat, moisture, and light. The specific shelf life or expiration date is printed on the original container/packaging.

Q: Will I need to take Alfuzozin Aurobindo forever?

The drug is used for the long-term management of a chronic condition (BPH). Clinical trials support its use for up to one year, suggesting that the intended duration of therapy is often long-term, subject to ongoing medical evaluation.

Q: Can Alfuzozin Aurobindo cause stomach upset or nausea?

Official regulatory documents list Nausea as a common side effect of the medicine. Other gastrointestinal adverse events, such as diarrhea, abdominal pain, and a general feeling of stomach upset, have also been reported.

Q: What signs indicate that a side effect from Alfuzozin Aurobindo might be serious?

Serious side effects require immediate medical attention if experienced. These include fainting (syncope), a prolonged painful erection (priapism), chest pain, or signs of a severe allergic reaction like swelling of the face, tongue, or throat.

Q: Does alcohol consumption change the effect of Alfuzozin Aurobindo?

Yes, official warnings indicate that consuming alcohol can increase the blood pressure-lowering effect of the medicine. This combination may lead to or worsen symptoms such as dizziness or fainting.

Q: Can Alfuzozin Aurobindo cause or worsen headaches?

Yes, Headache is listed as one of the common side effects that may occur while taking this medication, according to the official safety profile.

Q: Do you have to take Alfuzozin Aurobindo at the exact same time every day?

The official prescribing information requires that the tablet be taken once daily and immediately after the same meal each day. This protocol is essential to ensure consistent drug absorption and the sustained effect of the extended-release formulation.

Q: Is it safe to take cold and flu medicine while on Alfuzozin Aurobindo?

Caution is advised regarding taking other medicines that can affect blood pressure, such as certain ingredients found in cold and flu products. You should consult a healthcare professional before combining them, as some combinations could lead to an increased risk of hypotension.

Q: Does Alfuzozin Aurobindo require regular blood tests?

The official label advises caution and monitoring in patients who have severe kidney or liver impairment. While not required for every patient, specific blood tests (e.g., liver function tests) may be necessary for those with these pre-existing conditions.

Q: Is it possible to have an allergic reaction to Alfuzozin Aurobindo?

Yes, the medicine is strictly contraindicated (must not be used) in patients with known hypersensitivity (an allergic reaction) to alfuzosin, other related drugs, or any component of the tablet.

Q: What happens when you stop taking Alfuzozin Aurobindo?

Alfuzosin treats symptoms of BPH. The drug's therapeutic effects on urinary symptoms are generally reversible, meaning that if the medicine is discontinued, the symptoms may gradually return.

Q: Does Alfuzozin Aurobindo affect PSA levels?

Research suggests that Alfuzosin does not appear to cause significant or clinically relevant changes in your Prostate-Specific Antigen (PSA) blood test levels, unlike some other drug classes used for BPH.

Q: Can Alfuzozin Aurobindo be used with a statin medication for cholesterol?

Statins (HMG-CoA reductase inhibitors) are not listed among the major contraindicated or caution-required drug interactions in the official product label. However, all combinations of medications should be reviewed by a healthcare professional.

Q: Are there any long-term side effects associated with Alfuzozin Aurobindo use?

Clinical trials support the use of the drug for up to one year, and the reported adverse reactions are documented based on both short- and long-term use. However, follow-up durations were limited in many primary trials, meaning long-term outcomes are not fully characterized.

Q: What are common patient experiences when starting Alfuzozin Aurobindo?

When starting the medicine, common experiences can include effects like dizziness, headache, or a general feeling of tiredness (asthenia). These effects are noted to occur primarily at the beginning of the treatment course.

Q: Is a runny nose a reported side effect of Alfuzozin Aurobindo?

Yes, the official list of adverse reactions includes Rhinitis (inflammation of the nasal passages), which can cause symptoms like a runny nose. This is classified as an uncommon side effect.

Advertisements

How should Alfuzozin Aurobindo be stored and disposed of?

How to Store and Dispose of Alfuzosin Aurobindo?

Alfuzosin Hydrochloride extended-release tablets must be stored according to specific regulatory conditions to maintain their integrity.

Required Storage Conditions

Requirement Specification
Temperature Range Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Environmental Protection Protect from excess heat, moisture, and light.
Packaging Keep in the container it came in, with the container tightly closed.

Safety and Disposal

The medication must be kept out of the reach and sight of children.

Disposal of unused or expired tablets must comply with local regulations for pharmaceutical waste. Authorities recommend utilizing a drug take-back program whenever possible. If a take-back option is unavailable, the tablets should be mixed with an unappealing substance, sealed in a bag, and disposed of in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alfuzozin Aurobindo found in:

A-Z Index: